

Effectiveness of a six-month isoniazid on prevention of incident tuberculosis among people living with HIV in Eritrea: a retrospective cohort study

Mulugeta Russom^{1,2,6}, Henok G. Woldu³, Araia Berhane⁴, Daniel YB. Jeannetot², Bruno H. Stricker⁵, Katia Verhamme²

¹Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea.

²Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, the Netherlands.

³The Center for Health Analytics for National and Global Equity, Columbia, MO, USA.

⁴Communicable Disease Control Division, Department of Public Health, Ministry of Health, Asmara, Eritrea.

⁵Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.

⁶European Program for Pharmacovigilance and Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

Correspondence: Mulugeta Russom, e-mail: satiswt@gmail.com

S1: Classification of patients' level of adherence to ART/IPT in Eritrea during the study period conducted between November 1, 2014 and November 1, 2020		
Adherence category to ART/IPT	definition	Remarks
Good	>95%	A patient was considered as having 'good' adherence if he/she missed ≤ 3 doses per month.
Fair	85-94%	A patient was considered as having 'fair' adherence if he/she missed 4-8 doses per month.
Poor	<85%	A patient was considered as having 'poor' adherence if he/she missed ≥ 9 doses per month.
<i>ART: Anti-Retroviral Therapy; IPT: Isoniazid Preventive Therapy</i>		

S2: Study Questionnaire
Effectiveness of Isoniazid Preventive Therapy on the Prevention of Tuberculosis
among People Living with HIV in Eritrea: a Retrospective Cohort Study - 2020

Part I: Area/patient Identification

Zoba.....	<input type="text"/>
Hospital	<input type="text"/>
Exposure status [HAART + IPT = 1 and HAART only = 2]	<input type="text"/>
Patient serial number (<i>start with 0001</i>).....	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>

Part II: Patient socio-demographic characteristics

S/No	Questions and Filter	Coding Categories	Skip
201.	Patient card number	_____	
202.	Age of the patient in completed years (<i>take first recorded within study period</i>)	<input type="text"/> <input type="text"/>	
203.	Sex of the patient	Male 1 Female 2	
204.	Body weight in completed Kgs (<i>take first recorded within study period</i>)	<input type="text"/> <input type="text"/> <input type="text"/>	
205.	Level of education	No formal education 1 Primary 2 Secondary 3 Higher education 4	
206.	Residence	Asmara 1 Outside Asmara 2 Other 3	
207.	Known history of smoking?	Yes 1 No 2 Unknown 3	} 209
208.	Smoking status	Current smoker 1 Former smoker 2 Unknown 3	
209.	Known history of alcohol use?	Yes 1 No 2 Unknown 3	
210.	CD4 count (<i>take first record during the study period</i>)	_____	
211.	Viral load (<i>take first record during the study period</i>)	_____	
212.	Employment status	Employed 1 Unemployed 2 Unknown 3	
213.	Any co-morbidities?	Yes 1 No 0	→ 215
214.	What are the co-morbidities?	Diabetes A Hypertension B Cancer C COPD D	

		Other (specify).....E	
215.	Any history of malnutrition during the study period?	Yes 1 No 2 Unknown 3	
216.	Any history of prison during the study period?	Yes 1 No 2 Unknown 3	
217.	Any history of close contact with a person having TB during the study period?	Yes 1 No 2 Unknown 3	
218.	Current follow-up status?	Still on follow-up 1 Transferred 2 Lost-to-follow up 3 Died 4	} 301
219.	Date of death	___/ ___/___ (date/month/year)	
220.	Possible cause of death (Multiple answers are possible)	TB 1 Other OIs including pneumonia 2 Hepatic injury 3 Cancer 4 Other, specify 6 Unknown 5	
Part III: Exposure status, adherence and treatment outcome			
301.	Date HAART started?	___/ ___/___ (date/month/year)	
302.	Date of last follow-up (in years or months)	___/ ___/___ (date/month/year)	
303.	Type of HAART patient has taken during the study period? (If patient has shifted to multiple regimens, take the regimen taken for the longest period of time)	Nevirapine based 1 Efavirenz based 2 Second-line 3 Other (specify) 4	
304.	Level of adherence of patient towards HAART?	Good 1 Fair 2 Poor 3 Unknown 4	
305.	Has the patient received IPT?	Yes 1 No 2	→ 310
306.	Any history of interruption of IPT?	Yes 1 No 2 Unknown 3	
307.	Date IPT started?	___/ ___/___ (date/month/year)	
308.	Date last refill of IPT?	___/ ___/___ (date/month/year)	
309.	Total number of INH tablets/doses supplied (excluding the last refill)?	_____	
310.	Was the patient diagnosed with TB?	Yes 1 No 2 Unknown 3	} End
311.	When was the patient diagnosed with TB? (Multiple answers are possible)	Before Nov. 1, 2014 A After Nov. 1, 2014 B	
312.	If patient was diagnosed after November 1, 2014, was it before initiation of IPT?	Yes 1 No 2	

	<i>(If patient did not receive IPT, choose 'non applicable')</i>	Unknown 3 Not applicable 4	
313.	Date patient diagnosed with TB <i>(provide means of diagnosis in the last column of the respective dates)</i>	___/ ___/ ____ <i>(date/month/year)</i>	
		___/ ___/ ____ <i>(date/month/year)</i>	
		___/ ___/ ____ <i>(date/month/year)</i>	

Part IV: Data collector's detail: Name: _____ Tel: _____ Sig. _____

S3: Listing form for excluded cases of a study that assessed the effectiveness of Isoniazid Preventive Therapy (IPT) in people living with HIV in Eritrea conducted between Nov 1, 2014 and Nov 1, 2020

Hospital: _____

Serial No.	Card number	Reason for exclusion (code A, B, C, D, E or F as per the below listed criteria)	Serial No.	Card number	Reason for exclusion (code A, B, C, D, E or F as per the below listed criteria)
1.			26.		
2.			27.		
3.			28.		
4.			29.		
5.			30.		
6.			31.		
7.			32.		
8.			33.		
9.			34.		
10.			35.		
11.			36.		
12.			37.		
13.			38.		
14.			39.		
15.			40.		
16.			41.		
17.			42.		
18.			43.		
19.			44.		
20.			45.		
21.			46.		
22.			47.		
23.			48.		
24.			49.		
25.			50.		

- A. Exposure to IPT/ART for less than one year during the follow-up period
- B. IPT interrupted and could not complete the six months regimen
- C. Transferred in, IPT completed, but no data on IPT start date
- D. Unexposed to ART during follow-up period
- E. Patient diagnosed with TB (had active TB) while starting ART
- F. Others (Specify)